PL1648412T3 - Mikroemulsje i ich zastosowanie do zapobiegania chorobom dróg oddechowych - Google Patents

Mikroemulsje i ich zastosowanie do zapobiegania chorobom dróg oddechowych

Info

Publication number
PL1648412T3
PL1648412T3 PL04743268T PL04743268T PL1648412T3 PL 1648412 T3 PL1648412 T3 PL 1648412T3 PL 04743268 T PL04743268 T PL 04743268T PL 04743268 T PL04743268 T PL 04743268T PL 1648412 T3 PL1648412 T3 PL 1648412T3
Authority
PL
Poland
Prior art keywords
microemulsions
airway diseases
preventing airway
particles
polar lipid
Prior art date
Application number
PL04743268T
Other languages
English (en)
Inventor
Per Wollmer
Morgan Andersson
Lennart Greiff
Thomas Landh
Original Assignee
Nares Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0302006A external-priority patent/SE0302006D0/xx
Priority claimed from SE0302005A external-priority patent/SE0302005D0/xx
Application filed by Nares Ab filed Critical Nares Ab
Publication of PL1648412T3 publication Critical patent/PL1648412T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL04743268T 2003-07-07 2004-07-07 Mikroemulsje i ich zastosowanie do zapobiegania chorobom dróg oddechowych PL1648412T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48466403P 2003-07-07 2003-07-07
SE0302006A SE0302006D0 (sv) 2003-07-07 2003-07-07 New Microemulsions
SE0302005A SE0302005D0 (sv) 2003-07-07 2003-07-07 New composition
EP04743268A EP1648412B1 (en) 2003-07-07 2004-07-07 Microemulsions and its use for preventing airway diseases
PCT/GB2004/002925 WO2005004843A1 (en) 2003-07-07 2004-07-07 Microemulsions and its use for preventing airway diseases

Publications (1)

Publication Number Publication Date
PL1648412T3 true PL1648412T3 (pl) 2008-04-30

Family

ID=34068955

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04743268T PL1648412T3 (pl) 2003-07-07 2004-07-07 Mikroemulsje i ich zastosowanie do zapobiegania chorobom dróg oddechowych

Country Status (7)

Country Link
EP (1) EP1648412B1 (pl)
JP (2) JP5037939B2 (pl)
AT (1) ATE378038T1 (pl)
DE (1) DE602004010130T2 (pl)
ES (1) ES2297442T3 (pl)
PL (1) PL1648412T3 (pl)
WO (1) WO2005004843A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504805A (ja) 2005-08-09 2009-02-05 ナノバイオ コーポレーション 抗炎症活性を有するナノエマルジョン組成物
CN101360481A (zh) 2005-11-22 2009-02-04 雀巢技术公司 水包油乳液及其用于功能性输送的用途
JP4686763B2 (ja) * 2006-01-31 2011-05-25 独立行政法人産業技術総合研究所 針一体型バイオセンサー
EP2349209A2 (en) * 2008-09-26 2011-08-03 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
AR096459A1 (es) * 2013-06-03 2015-12-30 Tolmar Inc Composiciones de corticosteroides y método de fabricación
KR101743142B1 (ko) 2015-09-09 2017-06-02 강원대학교산학협력단 즉시 사용가능한 마이크로에멀젼 기반의 비강내 면역화용 면역보강제 조성물
CN110200915A (zh) * 2019-05-14 2019-09-06 扬子江药业集团江苏紫龙药业有限公司 一种富马酸卢帕他定乳剂型鼻腔喷雾剂及其制备方法
JP7505930B2 (ja) * 2020-06-29 2024-06-25 小林製薬株式会社 濃縮鼻腔粘膜洗浄用組成物
JPWO2022030607A1 (pl) * 2020-08-06 2022-02-10
IT202000024484A1 (it) * 2020-10-16 2022-04-16 Synapticom S R L Soluzione liposomiale con capacita’ di interagire con il particolato atmosferico, nelle cavita' nasali riducendo la velocita' di assorbimento delle particelle inspirate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1291036C (en) * 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
JP3324264B2 (ja) * 1994-03-23 2002-09-17 大正製薬株式会社 鼻洗浄剤
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
DE69527624T2 (de) * 1994-05-20 2003-04-03 Novavax, Inc. Antimikrobielle öl-in-wasser-emulsionen
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
JP2001513493A (ja) * 1997-08-09 2001-09-04 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 経鼻投与用組成物
US6015832A (en) * 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
JP2000109425A (ja) * 1998-10-02 2000-04-18 Lion Corp 花粉破裂防止剤、花粉破裂防止方法及び粘膜用洗浄剤
US6506803B1 (en) * 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6635676B2 (en) * 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6296882B1 (en) * 2000-06-12 2001-10-02 Manuel Viamonte, Jr. Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, and lemon oil
AUPQ875700A0 (en) * 2000-07-13 2000-08-03 Reflex Research Limited Combination compositions

Also Published As

Publication number Publication date
JP2012051892A (ja) 2012-03-15
EP1648412B1 (en) 2007-11-14
WO2005004843A1 (en) 2005-01-20
JP5037939B2 (ja) 2012-10-03
JP5604395B2 (ja) 2014-10-08
DE602004010130T2 (de) 2008-09-18
ES2297442T3 (es) 2008-05-01
ATE378038T1 (de) 2007-11-15
EP1648412A1 (en) 2006-04-26
DE602004010130D1 (de) 2007-12-27
JP2007526885A (ja) 2007-09-20

Similar Documents

Publication Publication Date Title
EP4360651A3 (en) Glp-1 compositions and uses thereof
NO20073559L (no) Nanopartiklulaere tacrolimus-formuleringer
PT1268498E (pt) Fosfonatos cardioprotectores
WO2007136439A3 (en) Hyperpolarization methods, systems and compositions
WO2006031606A3 (en) Carboxamide spirolactam cgrp receptor antagonists
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
NO20070785L (no) Sammensetninger for levering av svaert vannloselige medikamenter.
PL1613720T3 (pl) Czyszczące kompozycje emulsji wielokrotnych
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
PL1648412T3 (pl) Mikroemulsje i ich zastosowanie do zapobiegania chorobom dróg oddechowych
WO2006081363A3 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
DK1317254T3 (da) Retardpartikeldispersion
WO2004009091A8 (en) Purine derivatives as liver x receptor agonists
BRPI0417366A (pt) composição detergente lìquida, método de limpeza de um substrato de tecido, e, uso de um antioxidante
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
WO2020260956A3 (en) Self-emulsifying cannabidiol formulations
TW200716172A (en) Pharmaceutical compositions for treating lower motor neuron diseases
WO2014064652A3 (en) Stable pharmaceutical composition of peginterferon alpha-2b
WO2007005672A3 (en) Treatment and prevention of respiratory diseases and conditions
PL1765337T3 (pl) Połączenie tenofowiru, ritonawiru i TMC114
TNSN03065A1 (en) BIOPESTICIDE COMPOSITIONS
TW200730190A (en) New combination to treat liver fibrosis
ATE358992T1 (de) Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis
WO2007026071A8 (fr) Utilisation de dha sous forme de phospholipides pour la preparation d'une composition destinee au traitement de l'insuffisance respiratoire.